Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Stock Price Down 5.7% – Here’s What Happened

Inspira Technologies OXY B.H.N. Ltd. (NASDAQ:IINN)’s stock price fell 5.7% on Monday . The company traded as low as $0.36 and last traded at $0.3723. 1,052,194 shares changed hands during mid-day trading, an increase of 212% from the average session volume of 337,026 shares. The stock had previously closed at $0.3950.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Inspira Technologies OXY B.H.N. in a research report on Friday, April 10th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $2.00.

Inspira Technologies OXY B.H.N. Stock Up 2.4%

The company has a quick ratio of 1.30, a current ratio of 1.56 and a debt-to-equity ratio of 0.08. The company has a fifty day moving average price of $0.48 and a two-hundred day moving average price of $0.73.

Institutional Trading of Inspira Technologies OXY B.H.N.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in shares of Inspira Technologies OXY B.H.N. in the 4th quarter worth approximately $71,000. Citadel Advisors LLC bought a new stake in shares of Inspira Technologies OXY B.H.N. in the 3rd quarter worth approximately $105,000. Finally, Yorkville Advisors Global LP bought a new stake in shares of Inspira Technologies OXY B.H.N. in the 4th quarter worth approximately $1,605,000. 12.72% of the stock is currently owned by institutional investors.

Inspira Technologies OXY B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.